It is well to be noted that Lilly has now made a huge $3 billion, decade-long pledge to grow its manufacturing operations in China. This commitment shows that the company has big plans as far as its future is concerned. This goes on to make shareholders ask a crucial question – Why should they make such a big bet on China right now, when the world looks so complicated? The answer shows a masterclass in strategic foresight and provides Lilly a clear plan for how to grow in the future.

Why China? A once-in-a-lifetime chance in the market

Investors should first understand how big the opportunity is so as to understand the strategy by Lilly. This investment happens to be a direct response to a market that is too big to be overlooked. There is indeed a very big public health problem in China due to the fact that 141 million people there suffer from diabetes. In addition, the country has the largest population of overweight or obese adults in the world, with over 600 million of them. As the middle class expands in China and healthcare costs climb, the need for effective treatments is going to increase greatly.

This goes on to make a huge pool of potential patients for the best drugs from Lilly that is mostly untapped. There is a lot of money to be made right away. Market forecasts say that the GLP-1 diabetes and obesity drug market in China is likely to grow quickly in the next few years, and some analysts even happen to think that it could be worth around fourteen billion dollars by the end of this decade. This sort of fast growth makes China the most vital long-term growth engine when it comes to the main injectable products from Lilly and, most importantly, for its next wave of innovations, such as the oral drug orforglipron. For every day oral medication to work well on a large scale, it needs to be made locally and, too, in large quantities in an efficient way. To stay at the top of the world, one must secure this market.

Lilly’s Great Wall – A Plan for Supply as well as Power

Eli Lilly’s investment happens to be quite a smart strategy that serves two purposes. At the same time, it also builds a shield against the outside threats and an offensive weapon in order to take over the market. This sort of a proactive approach should make investors feel good about the ability of the management to deal with a complicated global environment and also protect the future profits of the company.

The Geopolitical Shield

The fact is that the strategy protects the supply chain, which goes on to act as a defensive shield. The U.S. pharmaceutical industry depends pretty heavily on China for Active Pharmaceutical Ingredients – APIs which are the main parts of many drugs. This reliance is indeed quite a big risk in a time when trade is tense. Lilly protects its most important growth market from prospective export controls or issues with logistics through building a strong presence in China. This choice, which was based upon what was learned from recent global GLP-1 diabetes and obesity drug shortages, guarantees an ongoing and predictable supply of medicine to the Chinese patients, increases loyalty for the brand, and gives shareholders dependable revenue streams that are not impacted by geopolitical instability.

The Weapon of Competition

More importantly, the investment happens to be an offensive weapon in a very competitive market. Lilly is fighting on two fronts when it comes to China. Novo Nordisk, which is its biggest competitor in the world, already does have a large and well-established manufacturing base in the country. The investment made by Lilly is indeed quite a necessary step to make things fair and compete hard in terms of supply and speed, as well as scale.

The fact is that even a wave of local competition may be more critical. Over 60 Chinese pharmaceutical companies are working on their own GLP-1 drugs. Such competition will put a lot of pressure on prices in the years to come. Lilly can save more money through making things in the area and working with regional specialists such as Pharmaron. This strategy lets it change its prices so as to protect its market share against less expensive alternatives in the future, which hence safeguards its long-term profit margins and also builds quite a strong competitive moat.

Why This Move Will Pay Off in the Future

In the end, this kind of a multi-billion-dollar plan directly supports the positive investment case for the stock of Eli Lilly. This is not just about making more sales, but it is more about building a strong, safe, as well as very profitable business for the long term.

The move happens to be quite a strong driver of the top-line growth that Lilly needs to keep its high valuation. Getting a big piece of the GLP-1 market in China could also mean billions of dollars in annual sales in the future, hence giving the company a long runway for growth, which makes it the market leader.

This sort of forward-thinking use of capital is a big reason why Wall Street is still very positive. The average price target for the stock of Lilly is around $1,230, and the analysts agree that it should be a moderate purchase. This hope is based on the fact that Mounjaro as well as Zepbound are doing well right now; however, it is also looking ahead to the future, when management is anticipated to continue making bold, strategic moves in order to ensure future growth. This kind of an investment in China shows that one can trust that.

Interestingly, Lilly is not only accelerating by adding this kind of a strong third pillar of global growth next to the U.S. as well as Europe, but it is also diversifying and bolstering its whole business. Investors do not see this $3 billion commitment as a risk, but it is for sure a well-thought-out and necessary step for the growth of Lilly over the next decade. It strengthens the position of Eli Lilly as an international player in pharmaceuticals and also makes a strong case when it comes to its long-term value.

The post Eli Lilly GLP-1 Diabetes and Obesity Drug Drive China Pledge appeared first on Pharma Advancement.

“You’re going to save a fortune and this is also so good for overall health care,” Trump said at the White House event announcing the site’s launch.

The TrumpRx direct-to-consumer drug site does not sell medicines directly. Instead, it acts as a central hub that redirects users to pharmaceutical companies offering discounted drugs through their own direct-to-consumer platforms or provides printable coupons redeemable at pharmacies.

At launch, TrumpRx lists medicines from five companies that recently struck pricing agreements with the administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer. Additional manufacturers are expected to be added in the coming months, according to the White House.

The service is intended for use by cash-paying consumers. Patients who do not have insurance or who are underinsured will likely benefit the most. Patients with insurance will likely gain less benefit, as TrumpRx purchases will probably not apply to deductibles or out-of-pocket maximums.

“If they’re able to get a drug covered by their insurance at a relatively affordable copay, then there’s not a great upside to using the TrumpRx website,” said Juliette Cubanski, deputy director of the program on Medicare Policy at KFF.

Among the well-known drugs already listed on the site are Novo Nordisk GLP-1 medicines Ozempic and Wegovy and Eli Lilly’s weight-loss injection Zepbound. Prices advertised on TrumpRx can involve significant discounts off the list price, although analysts warn that figure may be far from what consumers actually save compared with negotiated insurer prices.

TrumpRx marks the official debut of Trump’s “most favored nation” drug pricing policy intended to link US prices to those in other wealthy nations. While some have praised the effort for potentially increasing access to some expensive drugs, others say it fails to meaningfully lower prices or help most Americans with health insurance.

The post TrumpRx Direct-To-Consumer Drug Site Launches in the US appeared first on Pharma Advancement.

The investment strengthens DHL Health Logistics Singapore as demand grows for secure, compliant logistics that support increasingly complex global healthcare supply chains. Singapore’s biomedical sector produces goods valued at nearly S$38 billion, requiring infrastructure capable of handling high volumes of temperature-sensitive and regulated products.

Timely delivery and quality assurance are critical components within every link of today’s healthcare supply chain. Whether shipping pharmaceuticals or transporting medical devices, efficient handling, temperature controls and compliance standards affect patient care and research initiatives. DHL’s enhanced capabilities support Singapore as a distribution hub for life sciences products across the region.

DHL’s international network reaches over 220 countries and territories and can facilitate healthcare shipments from anywhere in the world using DHL’s GDP- and GMP-compliant facilities. DHL Health Logistics offers a healthcare-specific warehouse, medical courier network and certified experts who can manage your temperature-sensitive shipments.

The new pharmaceutical hub near Tuas Biomedical Park features specialised temperature zones and GMP-compliant infrastructure, offering strong connectivity to Changi Airport and Tuas Mega Port. The facility forms part of DHL Group’s broader €500 million regional investment plan in health logistics through 2030.

Segments covered by DHL Health Logistics services span pharmaceutical logistics for vaccines and pharmaceuticals, clinical logistics for investigational medicinal products (IMP) and medical device logistics, which includes last-mile delivery and aftermarket services. It also handles shipments of speciality pharmaceuticals that require ambient, chilled, frozen, refrigerated, temperature-controlled and cryogenic shipments. Other areas of support include consumer healthcare fulfilment and humanitarian health logistics.

Operating a wider footprint across healthcare segments enables DHL to better address the goals set out in its DHL Group Strategy 2030. The conglomerate’s new strategy is built around specialised infrastructure, digitalisation and resilience in supply chains worldwide. The ramping up of healthcare capacity in Singapore will help DHL safely and efficiently ship life science products and provide continuity to health system

The post DHL Health Logistics Singapore Invests in €10m Pharma Hub appeared first on Pharma Advancement.

The partnership between Lupin and TB Alliance will enable both organizations to facilitate the development of Telacebec and wider access for patients. TB Alliance will remain responsible for clinical development efforts while Lupin will apply its global manufacturing, regulatory and supply chain skills to aid in multi-market distribution.

“This collaboration with TB Alliance underscores Lupin’s enduring commitment to improving patient outcomes in areas of significant unmet medical need,” said Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin. “By leveraging our manufacturing scale and global distribution capabilities alongside TB Alliance’s deep expertise in drug development, we aim to enable timely and equitable access to Telacebec and contribute meaningfully to the global fight against tuberculosis, leprosy, and Buruli ulcer.”

Telacebec, previously known as Q203, is currently being developed as a potential new medicine to treat people with mycobacterial infections. There will be a focus on swift and responsible development and continued access.

“Telacebec represents the kind of scientific innovation that has the potential to transform treatment for diseases that have long been neglected,” said Mel Spigelman, MD, President and CEO, TB Alliance. “By partnering with Lupin, we are combining deep scientific expertise with global Chemistry, Manufacturing and Controls and access capabilities to help move this promising compound forward as quickly and responsibly as possible, with the ultimate goal of delivering better treatment options to people affected by tuberculosis, leprosy, and Buruli ulcer around the world.”

The post Lupin and TB Alliance Partner to Advance Telacebec Treatment appeared first on Pharma Advancement.

The companies plan to invest up to $1 billion over five years in talent, infrastructure and computing resources to support the lab, which will be based in the San Francisco Bay Area. The facility will bring together Lilly experts in biology, chemistry and medicine with NVIDIA engineers and AI model builders, working side by side to generate large-scale data and develop advanced AI models using the NVIDIA BioNeMo platform.

“AI is transforming every industry, and its most profound impact will be in life sciences,” said Jensen Huang, founder and CEO of NVIDIA. “NVIDIA and Lilly are bringing together the best of our industries to invent a new blueprint for drug discovery — one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made.”

“For nearly 150 years, we’ve been working to bring life-changing medicines to patients,” said David A. Ricks, chair and CEO of Lilly. “Combining our volume of data and scientific knowledge with NVIDIA’s computational power and model-building expertise could reinvent drug discovery as we know it. By bringing together world-class talent in a startup environment, we’re creating the conditions for breakthroughs that neither company could achieve alone.”

Initial work at the NVIDIA and Lilly AI lab will focus on building a continuous learning system that links Lilly’s laboratory experiments with computational models, allowing AI-assisted experimentation to run around the clock. The approach is intended to help experiments, data generation and model development inform each other in real time.

The initiative builds on Lilly’s previously announced AI supercomputer and will leverage next-generation NVIDIA architectures, including Vera Rubin. The companies also plan to explore applying AI across clinical development, manufacturing and commercial operations, including the use of robotics, digital twins and multimodal models to improve efficiency and supply chain reliability.

Work at the new lab is expected to begin in South San Francisco early this year.

The post NVIDIA and Lilly AI Lab All Set to Transform Drug Discovery appeared first on Pharma Advancement.

According to Richard Yu, PhD, co-founder and CEO of Abalone Bio, the FAST platform’s capability to generate functionally active GPCR antibodies goes on to present an opportunity to push boundaries of rare activating antibodies discovery, and they believe that this partnership could also unlock new approaches when it comes to potential treatments for diseases having high unmet need, through targeting biology in a way that has long been regarded as intractable.

It is well to be noted that GPCRs are large and dynamic membrane proteins that need accurate structural adjustments in order to modulate their activities. Antibody agonists for GPCRs can provide specificity and also functionality that’s beyond what the present drugs offer, but discovering them still remains quite a pressing challenge. The FAST platform helps with direct measurement of functional activity of umpteen antibodies within a single experiment. These large-scale functional datasets quite distinctly fuel the proprietary AI-powered workflow of Abalone Bio in order to identify GPCR agonists without any kind of external data, like structural information. Unlike the traditional antibody discovery methods, which apparently focus on binding affinity, the approach by Abalone makes use of engineered cells in order to directly measure the antibody function at a scale that’s unmatched in order to produce the large-scale and quality data that’s required.

As per the terms of the agreement, both companies are going to contribute resources to the discovery and screening as well as assessment when it comes to the antibodies. All financial along with operational details remain confidential.

The post Abalone and Pfizer Partner on Rare Activating Antibodies appeared first on Pharma Advancement.

The company has gone ahead and bought the commercial rights for Byooviz from Biogen, and the product is now going to be available as a brand from Samsung Bioepis throughout many European countries as part of the ongoing expansion plans that it has.

It was in August 2021 that Byooviz went on to receive an approval from the European Commission – EC as a single-use vial when it comes to intravitreal administration – 0.5mg/0.05ml.

It is indicated for treatment in terms of visual impairment because of diabetic macular oedema, neovascular – wet age-related macular degeneration, visual impairment due to choroidal neovascularization, and proliferative diabetic retinopathy, as well as visual impairment because of macular oedema secondary to retinal vein occlusion – branch or central.

The Committee for Medicinal Products for Human Use – CHMP of the European Medicines Agency – EMA issued quite a positive opinion for the Byooviz pre-filled syringe – PFS in November 2025. The syringe is expected to enter the European market sometime in the second quarter of 2026.

Antonio Rito, the vice-president of Samsung Bioepis said that direct commercialization of Byooviz indeed a major milestone for Samsung Bioepis since the company continues to make its presence across Europe very robust through expanding its portfolio when it comes to directly commercialized products.

He added that making utmost use of the last three years of experience with Epysqli – eculizumab and the newly launched Obodence – denosumab along with Xbryk – denosumab in Europe, they are going to continue with their journey to become a completely integrated biopharmaceutical company having end-to-end capabilities right from development to commercialization.

They are going to work closely along with payers as well as healthcare professionals in order to make sure of a seamless access when it comes to their biosimilar medicines for patients who are in need.

In September 2023, Sandoz went on to collaborate with Samsung Bioepis in order to develop and also market a Stelara – ustekinumab, a biosimilar in the US, Canada, and Europe.

The post Samsung Bioepis Starts Direct Commercialization of Byooviz appeared first on Pharma Advancement.

Apparently, the Japanese pharmaceutical giant is all set to establish novel production facilities and also expand the present ones in four major regions:

• Japan – A 77 billion yen, or $491.7 million, investment within the Hiratsuka plant located in the Kanagawa Prefecture.
• Germany – A 140 billion yen, or $894 million, allocated when it comes to production sites located in Munich, to be completed by 2028.
• China – 24 billion yen, or $153 million, for a new facility based out of Shanghai, which is scheduled for completion by 2030.
• United States – 56 billion yen, which is equivalent to $357.8 million in terms of additional facilities at the present plant located in New Albany, Ohio, with the expansion all set to be over by October 2027.

All these strategic investments are designed in order to enhance the global manufacturing network of Daiichi Sankyo and make sure of a balanced supply of Enhertu, which has interestingly shown quite a promise when it comes to treating numerous forms of cancer, especially the HER2-positive breast cancer.

The expansion plans of Daiichi Sankyo go on to reflect the confidence by the company in the market potential of Enhertu. The drug, which has been developed in collaboration with AstraZeneca, went on to generate $3.75 billion when it came to combined sales in 2024. Industry analysts have gone on to predict that Daiichi Sankyo is sure going to maintain its dominance when it comes to the antibody-drug conjugate spectrum all through 2029, majorly because of the breakthrough impact of Enhertu when it comes to treating HER2-low breast cancer.

It is worth noting that the recent FDA approval when it comes to Enhertu is regarded as the first-line treatment in terms of unresectable or metastatic HER2-positive breast cancer when mixed with Perjeta from Roche, which, by the way, further strengthens its market position. This latest indication goes on to add to the growing list of approved uses of the drug since its first approval in 2019.

Hiroyuki Okuzawa, the CEO of Daiichi Sankyo, underlined that while some of such investments were planned much before the emergence of the potential pharmaceutical tariffs, the company is going ahead and taking a proactive approach in order to address the possible geopolitical risks. The diversification of manufacturing locations throughout multiple continents enables Daiichi Sankyo to go ahead and maintain flexibility in terms of production and also lessen the supply chain disruptions, if any.

The commitment by the company to expand its antibody-drug conjugate capabilities goes on to sync with its long-term strategy so as to strengthen its foothold when it comes to this fast-growing portfolio of the pharmaceutical industry. As Daiichi Sankyo consistently advances to invest within its global manufacturing network, it is also positioning itself to meet the growing demand for Enhertu and also the potential future when it comes to ADC therapies.

The post Daiichi Sankyo Plans to Boost Its Antibody-Drug Conjugate appeared first on Pharma Advancement.

As per the 20-year licensing agreement, Chengdu Suncadia, which is Hangrui’s subsidiary, has agreed on a commercialization services framework along with Jiangsu Hansoh, as per which the latter is going to offer non-exclusive commercialization services when it comes to an entrusted product. Due to the fact that Hansoh Pharma is controlled by the Hengrui chairman’s spouse, both deals are classified as two continuing connected transactions as per the Hong Kong listing rules, thereby triggering reporting along with annual review requirements; however, they are exempt from independent approval of shareholders, while the unusually long 20-year term in terms of the licensing deal calls for an opinion from an independent financial adviser on market practice, highlighting a heightened governance scrutiny when it comes to investors along with other stakeholders.

It is well to be noted that Jiangsu Hengrui is listed in Hong Kong and operates within the domestic PRC pharmaceutical market and also partners with industry peers in order to expand its product portfolio along with commercial reach.

The post Hengrui Pharma Inks 20-Year Licensing Agreement with Hansoh appeared first on Pharma Advancement.

A 64-week, late-stage study demonstrated that participants who took 25 mg of oral semaglutide once a day went on to lose an average of 16.6% of their body weight, as compared with 2.7% for those on a placebo. The pill was given a nod for chronic weight management within adults with obesity or overweight and a minimum of one related health condition, therefore widening the potential patient pool at a time when the insurers, employers, and governments are battling it out with spiraling healthcare expenses related to obesity. It could also help open the door to tens of millions of untapped patients in an international market, forecast to be somewhere around $150 billion a year by the next decade. As per chief AI officer Anand Iyer at Welldoc, a telehealth firm, there is going to be a huge uptake in the patient base that is about to be seen as new indications open up and as the oral versions hit the market. Novo’s executive vice president of U.S. operations, David Moore, said that a daily pill could also boost the interest and uptake of the drug. Novo is apparently manufacturing the pill in the United States in North Carolina and has been building up supplies of the pill for quite some time now to ensure that it has enough supply.

Around 40% of American adults are obese, as per the U.S. government data, and almost 12% say that they are at present on GLP-1 drugs, as per a poll published in November 2025 by KFF, the health policy research organization. Novo apparently had a first-to-market advantage in terms of injectables; however, it initially struggled to meet that explosive demand. Eventually, Lilly went ahead with its Zepbound, which now goes on to lead when it comes to weekly U.S. prescriptions. Novo, along with analysts, says that a weight-loss pill would very well address the injection hesitancy and hence lead to expansion in access.

According to managing director and partner at BCG, Christopher Chrisman, the pills are not going to displace or replace the injections, adding that some patients may prefer to go ahead with their weekly injections. However, the pills do offer clear benefits to some people. There is indeed a level of travel convenience and no requirement to have a fridge,” he added. Novo remarked that the 1.5-milligram starting dose of the Wegovy pill is going to be available in early January 2026. Novo as well as Lilly had gone on to agree to provide starter doses in terms of their weight-loss pills at $149 for every month for the U.S. government Medicare and Medicaid health insurance programs and also to cash-paying customers through the direct-to-consumer TrumpRx site from the White House.

Novo recently slashed the cash price for Wegovy to $349 per month, from $499. Mike Doustdar, the Novo CEO, said that in November 2025, people making use of the weight-loss drugs showed more consumer-like behavior as compared to its traditional diabetes patients, therefore acknowledging that the company is required to adapt to this and also bring in the new expertise. Whether another semaglutide product can go ahead and solve the current ills of Novo remains to be seen. The weight loss pill from Novo Nordisk, oral semaglutide, has to be taken in the morning on an empty stomach, which is 30 minutes prior to eating, drinking, or using any kind of other oral medication.

The post U.S. FDA Approves Weight Loss Pill from Novo Nordisk appeared first on Pharma Advancement.